3 completed, 1 withdrawn. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
Follow emactuzumab: new trials by email Literature Review of emactuzumab trials Research Report on emactuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Atezolizumab, Emactuzumab, Obinutuzumab - Lymphoma, Non-Hodgkin | Phase 1 | Withdrawn | Hoffmann-La Roche | 2018-03-14 | 2018-04-05 | |
| A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Emactuzumab, RO7009789 - Neoplasms | Phase 1 | Completed | Hoffmann-La Roche | 38 | 2016-05-09 | 2018-05-22 |
| A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Atezolizumab, Emactuzumab - Solid Cancers | Phase 1 | Completed | Hoffmann-La Roche | 221 | 2015-01-19 | 2020-08-27 |
| A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors Paclitaxel, RO5509554 - Advanced Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 217 | 2011-12-20 | 2018-03-16 |
Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
United States (4) · France (3) · Belgium (2) · Spain (1)
PMID 24898549, PMID 26179200, PMID 31114846, PMID 33097612, PMID 33161240, PMID 35577503
2014 (1), 2015 (1), 2017 (1)